zetia Drug Patent Profile

Which patents cover Zetia, and when can generic versions of Zetia launch?

Zetia is a drug marketed by Organon and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-five patent family members in thirty-eight countries.

The generic ingredient in ZETIA is ezetimibe. There are twenty-four drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ezetimibe profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zetia

A generic version of zetia was approved as ezetimibe by GLENMARK PHARMS LTD on June 26^th, 2015.

Summary for zetia

International Patents:	235
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	103
Patent Applications:	5,609
Drug Prices:	Drug price information for zetia
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for zetia
What excipients (inactive ingredients) are in zetia?	zetia excipients list
DailyMed Link:	zetia at DailyMed

See drug prices for zetia

See drug sales revenues for zetia

Pharmacology for zetia

Drug Class	Dietary Cholesterol Absorption Inhibitor
Physiological Effect	Decreased Cholesterol Absorption

Paragraph IV (Patent) Challenges for ZETIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZETIA	Tablets	ezetimibe	10 mg	021445	1	2006-10-25

US Patents and Regulatory Information for zetia

zetia is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002	AB	RX	Yes	Yes	7,612,058*PED				Y

Expired US Patents for zetia

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002	5,767,115

International Patents for zetia

See the table below for patents covering zetia around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	PA03006725	COMBINACIONES DE ACTIVADORES DEL RECEPTOR DE ACTIVACION DE PROLIFERACION PEROXISOMAL (PPAR) E INHIBIDORES DE ABSORCION DE ESTEROL, Y TRATAMIENTO PARA INDICACIONES VASCULARES. (COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS.)
Russian Federation	2003126184
Poland	313589
Canada	2434488
Australia	2002240050
Japan	2007211031	COMBINATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR AND STEROL ABSORPTION INHIBITOR AND TREATMENT FOR VASCULAR INDICATION

Supplementary Protection Certificates for zetia

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	CR 2014 00048	Denmark		PRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724
0720599	300689	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
0720599	CA 2005 00003	Denmark
0720599	03C0028	France		PRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017
0720599	05C0040	France		PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402
0720599	SPC001/2005	Ireland		SPC001/2005: 20050803, EXPIRES: 20190401

Market Dynamics and Financial Trajectory for ZETIA

Last updated: February 19, 2026

What is ZETIA and how does it perform in the market?

ZETIA (ezetimibe) is a cholesterol absorption inhibitor primarily used to lower low-density lipoprotein (LDL) cholesterol. It is marketed by Merck & Co. and approved by the FDA in 2002. ZETIA is prescribed as an adjunct to diet, exercise, and other lipid-lowering therapies, including statins.

Since its FDA approval, ZETIA has maintained a stable market presence. As of 2022, global sales approximated $2.1 billion, reflecting its role in combination therapies and stand-alone use. The drug's performance is influenced by the rise in hypercholesterolemia diagnosis and ongoing statin saturation, as well as its positioning within lipid management guidelines.

How does ZETIA fit within the competitive landscape?

Key competitors include PCSK9 inhibitors (e.g., Repatha and Praluent) and other oral cholesterol-lowering medications. ZETIA's advantages involve oral administration, a lower price point relative to PCSK9 inhibitors, and proven safety for long-term use.

Market share is estimated at approximately 6% within lipid-lowering agents globally. The dominance lies with statins, which account for over 70% of the market, while ezetimibe's share has stabilized due to shifting preferences in recent lipid management guidelines which increasingly favor PCSK9 inhibitors for high-risk populations.

What are the market drivers influencing ZETIA's sales?

Increasing prevalence of hypercholesterolemia

The global prevalence of high LDL cholesterol has increased from approximately 35% in 2000 to over 40% in 2020, according to the World Health Organization (WHO). Aging populations and lifestyle factors drive continued demand for cholesterol-lowering therapies.

Treatment guidelines and reimbursement policies

In 2018, the American College of Cardiology (ACC) and American Heart Association (AHA) recommended statins as the first line, with ezetimibe or PCSK9 inhibitors added for specific high-risk groups. Reimbursement for ezetimibe remains favorable in many markets, supporting ongoing prescriptions.

Patent and market exclusivity

Merck's patent for ZETIA expired in 2016 outside the U.S., leading to generic versions entering markets like Europe and Asia. Generic ezetimibe has compressed prices and marginal profit margins, though the branded version maintains a premium position in the U.S. with patent protections until 2025 at least.

New clinical data and combination formulations

Combination therapies, such as Vytorin (ezetimibe plus simvastatin), bolster utilization by simplifying treatment regimens. Positive results from trials like the IMPROVE-IT study (2015) showing improved outcomes when adding ezetimibe to statins sustain user confidence.

What is the financial outlook for ZETIA?

Revenue trends

Merck's ZETIA revenue has declined modestly from a peak of over $2.3 billion in 2014, due to generic erosion and competitive pressure. In the fiscal year 2022, ZETIA generated around $2.1 billion globally, a 4.3% decrease from 2020.

Geographic distribution

North America accounts for approximately 70% of sales, with the U.S. representing the most significant share due to higher penetration and reimbursement coverage. Europe contributes roughly 20%, and Asia-Pacific, 10%, with growth potential as cardiovascular disease prevalence rises.

Cost considerations

Prezzo for branded ZETIA remains near $300 per month per patient in the U.S., whereas generics have dropped below $50 in many markets. R&D expenditures for new formulations or combination drugs are relatively modest in comparison to revenue size.

Potential revenue impact from patent expiration

Patent expiry in key markets and the availability of generics could reduce revenues by an estimated 60-70% over the next five years if no new formulations or indications are approved.

What are future market trajectories and risks?

The nitric of growth hinges on regulatory approval for new indications, industry adoption of combination therapies, and evolving guidelines favoring more potent lipid-lowering agents. Risks include rising competition from PCSK9 inhibitors and generics, patent cliffs, and shifts in clinical practice favoring alternative therapies.

Key Market Opportunities and Challenges

Opportunity	Challenge
Rising cardiovascular disease	Patent expiration in developed markets
Expansion into emerging markets	Price competition from generics
Development of new formulations	Regulatory hurdles for new indications

Conclusion

ZETIA remains a significant player in lipid management, with stable revenues primarily supported by North American markets. Future growth prospects depend on regulatory strategies, pipeline innovation, and market share retention amid increasing competition.

Key Takeaways

• ZETIA generated approximately $2.1 billion globally in 2022, mainly from North America.
• Patent expiry and generic entry threaten revenue streams, with expected declines of 60-70% over five years.
• Industry trends favor combination therapies, sustaining ZETIA’s relevance.
• Market growth will be driven by increasing dyslipidemia prevalence, especially in emerging regions.
• Competitive pressure from PCSK9 inhibitors and shifting clinical guidelines pose long-term risks.

FAQs

1. When will generic ezetimibe impact ZETIA’s sales?
   Patent expiration outside the U.S. occurred in 2016; generics are now widely available, significantly impacting U.S. sales after patent expiry there in 2025.

2. Are there new indications for ZETIA?
   Currently, no new approved indications exist beyond cholesterol management. Future approvals depend on ongoing clinical trials.

3. How does ZETIA compare to PCSK9 inhibitors?
   ZETIA is less potent but is oral, less expensive, and has a well-established safety profile. PCSK9 inhibitors are injectable and more effective for high-risk patients.

4. What is the potential for ZETIA combined with other therapies?
   Combination formulations like Vytorin enhance adherence but face competition from newer agents and will need clinical validation for expanded use.

5. Which markets are expanding for ZETIA?
   Emerging markets in Asia and Latin America exhibit growth potential due to surging cardiovascular disease rates and increasing healthcare access.

---

References

[1] World Health Organization. (2020). Dyslipidemia prevalence global report.
[2] American College of Cardiology & American Heart Association. (2018). Lipid management guidelines.
[3] IMPROVE-IT Study. (2015). Ezetimibe added to statin therapy improves cardiovascular outcomes.
[4] IQVIA. (2022). Global pharmaceutical sales data.
[5] Merck & Co. Financial Reports. (2022). Annual revenue and product performance data.